Investor Presentation Q1-Q3 2020
66
Thrombin Peak (nM)
ه
Investor presentation First nine months of 2020
Next-generation FVIII mimentic, Mim8, is a bispecific antibody
for SC prophylaxis treatment in people with haemophilia A
400
300
200
100
Thrombin generation assay
HA plasma + FVIII
Mim8
emicizumab¹
150
Clot time, R-time (min)
50
100
Thromboelastography
50
Mim8
HA
emicizumab¹
HA
Normal control
0
0
TTTTTT
www
TITIE
0.1
1
10
100
1000
0.01
0.1
Antibody (nM)
1
Antibody (nM)
10
100
1000
Mim8 potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo
Mim8 effectively stops severe bleeds in mouse models
1 Sequence-identical-analogue (SIA) of the FVIII-mimicking bispecific antibody emicizumab; PK: pharmacokinetics; PD: pharmacodynamics; SC: subcutaneous
Characteristics
•
Strong activity at site of bleeding
• Minimised target binding in circulation
Delivered in an innovative device
Phase 1/2 trial
• Initiated in January 2020
•
Phase 1 is a single ascending dose part with
40 treated people
• Phase 2 is a multiple ascending dose part with
32 treated people
• Trial investigates safety, tolerability, PK/PD of
single sc injections
Novo Nordisk®View entire presentation